OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
002765 Landai Technology Group Corp.,
- 13.84
- -0.56-3.89%
Not Open Apr 1 15:00 CST
9.03BMarket Cap72.46P/E (TTM)
14.82High13.76Low687.44KlotVolume14.54Open14.40Pre Close977.02MTurnover11.54%Turnover Ratio72.46P/E (Static)652.13MShares17.1252wk High3.66P/B8.25BFloat Cap4.0152wk Low15.84Limit Up595.91MShs Float20.79Historical High12.96Limit Down7.36%Amplitude3.34Historical Low0.05Dividend TTM14.21Avg Price364.22KlotAsk0.36%Div YieldTTM100Lot Size276.70KlotBid
Landai Technology Group Corp., Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 25.93%3.54B | 25.86%2.61B | 27.35%1.62B | 24.51%752.45M | -2.29%2.81B | 0.36%2.08B | -6.21%1.27B | -21.01%604.32M | -8.47%2.87B | -9.01%2.07B |
| Operating revenue | 25.93%3.54B | 25.86%2.61B | 27.35%1.62B | 24.51%752.45M | -2.29%2.81B | 0.36%2.08B | -6.21%1.27B | -21.01%604.32M | -8.47%2.87B | -9.01%2.07B |
| Other operating revenue | -59.57%98.31M | ---- | -31.83%83.19M | ---- | 23.23%243.14M | ---- | 48.92%122.02M | ---- | -2.36%197.3M | ---- |
| Total operating cost | 21.04%3.37B | 24.48%2.51B | 27.93%1.56B | 26.07%734.84M | 4.80%2.79B | 5.26%2.02B | -2.92%1.22B | -17.43%582.88M | -8.37%2.66B | -8.31%1.92B |
| Operating cost | 23.02%3.05B | 27.70%2.27B | 32.75%1.42B | 32.91%669.86M | 4.72%2.48B | 3.81%1.77B | -4.81%1.07B | -20.35%504.01M | -7.93%2.37B | -8.34%1.71B |
| Operating tax surcharges | 4.80%20.15M | 3.12%12.47M | -1.77%8.66M | -30.89%2.01M | 5.74%19.22M | 11.47%12.1M | 18.31%8.82M | 17.40%2.91M | 18.58%18.18M | 41.29%10.85M |
| Operating expense | -2.42%48.86M | -0.24%42.74M | -3.38%23.93M | -1.06%10.67M | 13.41%50.07M | 10.21%42.85M | 27.50%24.77M | 7.76%10.78M | -17.31%44.15M | 14.79%38.88M |
| Administration expense | -0.55%102.81M | -14.52%76.33M | -21.03%45.57M | -22.27%23.21M | -12.24%103.38M | -1.83%89.29M | -1.46%57.7M | 9.21%29.86M | 15.76%117.8M | 29.57%90.95M |
| Financial expense | 52.21%8.09M | 13,620.23%16.68M | 962.81%5.05M | -69.33%2.81M | 128.16%5.31M | 100.48%121.59K | 93.45%-585.16K | 10.06%9.16M | -153.81%-18.86M | -220.15%-25.39M |
| -Interest expense (Financial expense) | 2.87%24.57M | 15.42%20.95M | -5.30%14.22M | -26.53%6.36M | -23.89%23.88M | -24.84%18.15M | -3.81%15.02M | 25.00%8.66M | 15.00%31.38M | 21.98%24.15M |
| -Interest Income (Financial expense) | 6.05%-12.17M | 4.17%-9.37M | -12.42%-6.42M | -0.35%-3.24M | -116.62%-12.95M | -140.59%-9.78M | -134.24%-5.71M | -272.04%-3.23M | -53.30%-5.98M | 4.14%-4.06M |
| Research and development | 10.69%144.26M | -1.05%98.93M | -2.58%59.49M | 0.47%26.28M | -0.67%130.32M | 7.08%99.98M | 5.29%61.06M | 4.75%26.16M | 4.22%131.2M | -0.77%93.37M |
| Credit Impairment Loss | 31.61%-13.43M | -25.43%-18.12M | -225.45%-7.87M | 914.92%3.6M | -301.60%-19.64M | -326.13%-14.45M | -123.38%-2.42M | -93.78%354.25K | 157.95%9.74M | 91.76%6.39M |
| Asset Impairment Loss | 82.04%-82.83M | -29.69%-26.69M | 23.81%-15.19M | -314.47%-6.9M | -790.40%-461.06M | 14.92%-20.58M | -4.23%-19.94M | 81.52%-1.66M | 26.45%-51.78M | 19.17%-24.19M |
| Adjustment items of total operating cost | ---- | ---- | ---- | ---- | ---- | ---- | -200.00%-0.01 | ---- | ---- | ---- |
| Other net revenue | 93.62%-26.11M | 88.78%6.69M | 188.42%13.23M | 24.04%16.59M | -3,232.17%-409.13M | -77.32%3.54M | -49.98%4.59M | 199.76%13.37M | -46.84%13.06M | -68.12%15.62M |
| Fair value change income | ---- | ---- | --0 | ---- | ---- | 95.65%-407.54K | 99.99%-1.08K | 92.77%-416.09K | -39.80%1.94M | -340.89%-9.38M |
| Invest income | -4.88%-2.38M | 126.48%377.18K | 137.47%481.49K | -21.37%354.53K | -84.06%-2.27M | -1,523.38%-1.42M | -290.07%-1.28M | -16.60%450.87K | -111.98%-1.24M | -98.80%100.08K |
| -Including: Investment income associates | 39.60%-101.22K | 92.21%-51.01K | 109.70%53.31K | 133.84%132.35K | 70.99%-167.59K | -15.65%-654.99K | -34.90%-549.6K | -272.59%-391.15K | 32.33%-577.65K | 23.46%-566.35K |
| Asset deal income | 100.51%49.6K | 28.84%-553.57K | -62.51%-881.77K | 93.31%121.16K | -827.37%-9.68M | 75.23%-777.97K | 82.90%-542.6K | 102.33%62.68K | -123.65%-1.04M | -162.35%-3.14M |
| Other revenue | -13.21%72.49M | 25.49%51.68M | 27.52%36.69M | 33.11%19.42M | 50.65%83.52M | -10.17%41.18M | -5.21%28.77M | -6.92%14.59M | -24.32%55.44M | -21.36%45.84M |
| Operating profit | 135.59%137.8M | 74.10%108.57M | 27.83%68.99M | -1.74%34.2M | -269.56%-387.16M | -62.85%62.36M | -49.01%53.97M | -45.27%34.81M | -13.21%228.32M | -27.73%167.85M |
| Add:Non operating Income | -98.34%125.79K | -89.65%67.36K | 285.72%52.57K | -99.92%0.45 | 11,436.86%7.57M | 941.66%650.99K | -75.58%13.63K | -99.66%532.47 | -14.90%65.63K | -95.42%62.5K |
| Less:Non operating expense | 17.26%4.46M | -52.81%1.11M | -91.25%163.68K | ---- | -15.25%3.81M | 65.24%2.36M | 1,392.81%1.87M | 5,166.82%684.59K | 145.38%4.49M | 87.21%1.43M |
| Total profit | 134.81%133.46M | 77.28%107.53M | 32.17%68.88M | 0.23%34.2M | -271.23%-383.39M | -63.57%60.65M | -50.73%52.11M | -46.46%34.12M | -14.32%223.9M | -28.51%166.48M |
| Less:Income tax cost | 165.90%8.14M | 369.01%2.66M | 284.60%1.63M | -104.69%-61.05K | -143.07%-12.35M | -107.96%-989.64K | -94.33%423.92K | -82.92%1.3M | 44.77%28.66M | -57.02%12.42M |
| Net profit | 133.78%125.33M | 70.12%104.87M | 30.10%67.25M | 4.39%34.27M | -290.05%-371.05M | -59.99%61.64M | -47.41%51.69M | -41.51%32.82M | -19.17%195.24M | -24.47%154.06M |
| Net profit from continuing operation | 133.78%125.33M | 70.12%104.87M | 30.10%67.25M | 4.39%34.27M | -290.05%-371.05M | -59.99%61.64M | -47.41%51.69M | -41.51%32.82M | -19.17%195.24M | -24.47%154.06M |
| Less:Minority Profit | 117.63%1.05M | 366.66%1.25M | -346.15%-371.46K | -184.38%-1.48M | -156.51%-5.94M | -105.59%-467.3K | -97.69%150.91K | -69.69%1.75M | -66.60%10.51M | -69.00%8.36M |
| Net profit of parent company owners | 134.04%124.28M | 66.83%103.62M | 31.20%67.62M | 15.06%35.75M | -297.65%-365.1M | -57.37%62.11M | -43.83%51.54M | -38.27%31.07M | -12.06%184.72M | -17.68%145.7M |
| Earning per share | ||||||||||
| Basic earning per share | 133.33%0.19 | 58.08%0.1584 | 25.85%0.1037 | 9.66%0.0545 | -278.13%-0.57 | -59.92%0.1002 | -48.14%0.0824 | -43.20%0.0497 | -13.51%0.32 | -19.35%0.25 |
| Diluted earning per share | 133.33%0.19 | 62.13%0.1584 | 26.31%0.1037 | 10.32%0.0545 | -278.13%-0.57 | -60.92%0.0977 | -47.94%0.0821 | -43.22%0.0494 | -11.11%0.32 | -19.35%0.25 |
| Other composite income | ||||||||||
| Total composite income | 133.78%125.33M | 70.12%104.87M | 30.10%67.25M | 4.39%34.27M | -290.05%-371.05M | -59.99%61.64M | -47.41%51.69M | -41.51%32.82M | -19.17%195.24M | -24.47%154.06M |
| Total composite income of parent company owners | 134.04%124.28M | 66.83%103.62M | 31.20%67.62M | 15.06%35.75M | -297.65%-365.1M | -57.37%62.11M | -43.83%51.54M | -38.27%31.07M | -12.06%184.72M | -17.68%145.7M |
| Total composite income of minority owners | 117.63%1.05M | 366.66%1.25M | -346.15%-371.46K | -184.38%-1.48M | -156.51%-5.94M | -105.59%-467.3K | -97.69%150.91K | -69.69%1.75M | -66.60%10.51M | -69.00%8.36M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Chongqing Kanghua Certified Public Accountants Firm (Special General Partnership) | -- | -- | -- | Chongqing Kanghua Certified Public Accountants Firm (Special General Partnership) | -- | -- | -- | Chongqing Kanghua Certified Public Accountants Firm (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.